Ask AI

Optimizing Immunotherapy Delivery and Safety in NSCLC

Text Module
Text Module Start Activity
This activity is available for 0.50 CME/CE credit(s).

Released: October 12, 2026

Expiration: April 11, 2027

See Activity Collection

The delivery and management of immunotherapy for non-small-cell lung cancer continue to evolve with the approval of subcutaneous immune checkpoint inhibitor formulations and increasing emphasis on proactive toxicity management. This text module explores the efficacy, safety, administration, resource use, and potential effects of subcutaneous immunotherapy on the patient experience. It also provides practical guidance for recognizing and managing immune-related adverse events and counseling patients and caregivers throughout treatment.

Immunotherapy Delivery in Early NSCLC

Pre Assessment

Assess your current knowledge and clinical approach before beginning your text module.
1.

How many people with non-small-cell lung cancer (NSCLC) do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 59-year-old man with PD-L1–positive (tumor proportion score 90%), advanced squamous NSCLC presents to your clinic. His Eastern Cooperative Oncology Group performance status is 0. He has a busy schedule working full time as the chief marketing officer for a fast food chain across the United States. He is interested in pursuing treatment with subcutaneous (SC) single-agent immune checkpoint inhibitor (ICI) but wants more information on how its efficacy compares with the intravenous (IV) formulation(s) given at infusion clinics.

 Which of the following would you tell this patient regarding the efficacy and safety data for SC vs IV anti–ICI in patients with PD-L1–positive NSCLC?​

4.

 A 56-year-old woman with resectable stage IIIA (T3N1M0) lung adenocarcinoma is receiving neoadjuvant chemoimmunotherapy followed by planned resection and adjuvant immunotherapy.​ After cycle 2, she develops persistent grade 2 diarrhea (5 stools/day over baseline) despite loperamide.​ Infectious workup is negative​.  

 Along with supportive care, which of the following is the optimal next step for management of this patient’s diarrhea?